RAPT Therapeutics stock surges 63% in pre-market trade on Nasdaq after GSK’s $2.2 billion acquisition deal
US-based biopharmaceutical company, RAPT Therapeutics’ stock surged more than 63% during the pre-market trading session on the US stock market’s Nasdaq after GSK Plc announced its $2.2 billion equity value acquisition deal, according to the official filing. On Tuesday, 20 January 2025, GSK Plc announced that the company had signed a definitive agreement to potentially…